首页> 外文期刊>Japanese journal of clinical oncology. >High-dose-rate intra-cavitary brachytherapy combined with external beam radiation therapy for under 40-year-old patients with invasive uterine cervical carcinoma: Clinical outcomes in 118 patients in a Japanese multi-institutional study, JASTRO
【24h】

High-dose-rate intra-cavitary brachytherapy combined with external beam radiation therapy for under 40-year-old patients with invasive uterine cervical carcinoma: Clinical outcomes in 118 patients in a Japanese multi-institutional study, JASTRO

机译:JASTRO在日本的一项多机构研究中,对40岁以下的浸润性宫颈癌患者进行大剂量腔内近距离放射治疗和外照射治疗:118例患者的临床结局

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The current study was designed to evaluate the clinical outcomes of curative intent radiation therapy for young patients with invasive uterine cervical carcinoma in Japan. Methods: One hundred and eighteen patients aged ≤40 were registered in the multi-institutional study of the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) from 26 major institutions in Japan. The age range was 24-39 years and the maximum tumor diameter was 2.0-9.2 cm. The International Federation of Gynecology and Obstetrics clinical stages were Ib, IIa, IIb, IIIa, IIIb and IVa in 17, 6, 40, 2, 50 and 3, respectively. Curative intent radiation therapy consisted of the combination of external beam radiation therapy and highdose rate intra-cavitary brachytherapy. The total dose of external beam radiation therapy ranged between 44 and 68 Gy. Both the median and mode of total high-dose-rate intra-cavitary brachytherapy dose to point A were 24 Gy in four fractions. Ninety-six patients (58%) received chemotherapy. Results: The 5-year overall survival rate and local control rate of all patients were 61 and 65%, respectively. The 5-year overall survival rates of International Federation of Gynecology and Obstetrics Stage Ib, IIa, IIb, IIIa, IIIb and IVa were 88, 100, 75, 100, 37 and 0%, respectively. The 5-year local control rates of International Federation of Gynecology and Obstetrics Stage Ib, IIa, IIb, IIIa, IIIb and IVa were 82, 75, 75, 100, 51 and 0%, respectively. Sixteen patients experienced grade 3 or greater late radiation morbidity. Conclusions: The 5-year overall survival rate of young patients with Stage IIIb was comparatively low at 37%.
机译:背景:本研究旨在评估日本侵袭性宫颈癌年轻患者根治性放射治疗的临床效果。方法:在日本26个主要机构的日本放射治疗与肿瘤学会(JASTRO)的多机构研究中注册了118名≤40岁的患者。年龄范围为24-39岁,最大肿瘤直径为2.0-9.2 cm。国际妇产科联合会的临床分期分别为17、6、40、2、50和3,分别为Ib,IIa,IIb,IIIa,IIIb和IVa。根治性放疗由外束放疗和高剂量率腔内近距离放疗组成。外部束放射治疗的总剂量在44至68 Gy之间。高剂量率腔内近距离放射治疗总剂量到A点的中位数和模式均为24 Gy,分为四个部分。九十六名患者(58%)接受了化疗。结果:所有患者的5年总生存率和局部控制率分别为61%和65%。国际妇产科联合会Ib,IIa,IIb,IIIa,IIIb和IVa期的5年总生存率分别为88%,100%,75%,100%,37%和0%。国际妇产科联合会Ib,IIa,IIb,IIIa,IIIb和IVa期的5年局部控制率分别为82%,75%,75%,100%,51%和0%。 16名患者出现3级或更高的晚期放射病发病率。结论:年轻IIIb期患者的5年总生存率相对较低,为37%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号